Please assess the completion status of the following clinical trial:

Trial Title: Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients being evaluated for Alzheimer disease and related dementias according to the HAS recommendations (atypical dementia, early onset and rapid progressive dementia)~* Patients who have previously been evaluated for AD and related dementias to whom a CSF examination was recommended in the last 12 months, but lumbar puncture was contraindicated or refused or CSF results were ambiguous, or~* Patients currently being evaluated for AD and related dementias to whom a CSF examination is recommended but lumbar puncture is contraindicated or refused~* Patients have a study partner who is willing and able to accompany him/her to all clinic visits for the duration of the protocol~* Patients able to complete all clinical visits according to the protocol~* Patients able to tolerate a 20-minute FBB PET scan~* Patient or legal representative to provide informed consent for study participation, visits and data source verification.~Exclusion Criteria:~* The subject had a previous beta amyloid imaging scan~* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol~* Is currently receiving any investigational pharmaceutical product or has participated in a clinical trial with an investigational pharmaceutical product within 30 days prior to screening and/or was administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study~* For females of childbearing age, a positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Neuraceq (florbetaben 18F) PET scan (Type: EXPERIMENTAL): A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.~The applied florbetaben radioactive dose will be ± 20%.

Based on this trial design, predict the completion outcome and termination type (if applicable).